| Date | Title | Description |
| 08.04.2026 | CNBC’s UK Exchange newsletter: Brace yourself for rising bills as new tax year kicks off | The new tax year has kicked off in the U.K.
Households and businesses are facing rising bills due to a range of measures introduced by the Labour government.
There will be some winners with mobile and broadband suppliers and water companies... |
| 07.04.2026 | Corporate Vision and Trade Confrontation: The Shifting U.S. Economic Narrative | Motorola Solutions CEO Greg Brown earns top honors, lauded for transforming the company into a global public safety and security technology leader. His strategic vision and operational prowess drove exceptional growth and innovation. Meanwh... |
| 06.04.2026 | Biotech Firm Gets a New Leader
New chief chosen | - |
| 04.04.2026 | Asian travelers seek respite in other options as Middle East travel plans stay grounded | Asian travelers reconsider their vacation plans due to rising airfare and safety concerns.
Last minute airfare changes are cited as the biggest reason for cancellations, experts say.
Cruises and alternative locations in the region have beco... |
| 03.04.2026 | Foundayo Arrives: Eli Lilly's Pill Set to Transform Weight Loss | Eli Lilly's Foundayo receives swift FDA approval. This daily oral GLP-1 pill targets obesity, expanding treatment options. Foundayo offers convenience and improved health outcomes, albeit with less weight loss than injectables. Competitive ... |
| 03.04.2026 | GLP-1 Revolution: Novo Nordisk Innovates Pricing, Expands Health Impact | Novo Nordisk aggressively reshapes the GLP-1 landscape. It launches multi-month Wegovy subscriptions in the U.S., ensuring predictable pricing and bolstering patient adherence against Eli Lilly's market dominance. Concurrently, the UK's NIC... |
| 02.04.2026 | Diabetes advocates cross their fingers as a bipartisan bill revives efforts to lower insulin costs | Getting your Trinity Audio player ready...
By ALI SWENSON
NEW YORK (AP) — Two-year-old Bain Brandon has Type 1 diabetes and needs insulin to live. But even with health insurance, the price tag isn’t cheap. Related Articles
Trump has private... |
| 02.04.2026 | Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions | Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's 2026 Scientific Sessions.
The presentati... |
| 02.04.2026 | Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs | The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC has learned.
The Trump administration is... |
| 02.04.2026 | 5 Things to Know
Trump’s address, SpaceX IPO, Sam’s Club membership prices and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Thursday. It’s the one-year anniversary of President Donald Trump’s initial tariff unveiling, what the president dubbed “liberation day... |
| 02.04.2026 | Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison | Oral Wegovy demonstrated “significantly greater mean weight loss” than Lilly’s rival pill Foundayo, which was approved this week, Novo Nordisk said Thursday.
Novo’s findings evaluated previously published studies of the medicines and did no... |
| 01.04.2026 | FDA approves Eli Lilly’s GLP-1 pill, opening the next phase of the weight loss drug market | The FDA approved a GLP-1 pill from Eli Lilly called Foundayo.
Foundayo isn’t as effective as Lilly’s weekly shot Zepbound, but the once-daily pill could be attractive for people looking for convenience, and it can be scaled around the world... |
| 01.04.2026 | FDA grants speedy approval to Eli Lilly’s weight-loss pill for obesity | Getting your Trinity Audio player ready...
By JONEL ALECCIA, AP Health Writer
Federal regulators on Wednesday approved Eli Lilly’s new weight-loss pill, a second daily oral medication to treat obesity and other weight-related conditions.
Th... |
| 01.04.2026 | Novo’s Wegovy cleared by UK drug price watchdog for heart disease, expanding access by 1.2 million people | Novo Nordisk weight loss drug Wegovy was recommended by England’s drug price regulator to prevent heart attacks and strokes.
The new recommendation from NICE will significantly expand access to Wegovy on the country’s National Health Servic... |
| 01.04.2026 | The Nomination Committee proposes two new Board members | The Nomination Committee proposes two new Board members
Wed, Apr 01, 2026 17:50 CET Report this content
Vitrolife AB (publ) ("Vitrolife") today announced that its Nomination Committee proposes the election of Nicklas Hansen and Da... |
| 31.03.2026 | India's Economic Ascent: Global Billions Fueling Sports, Retail, and National Growth | India’s economy surges, becoming a magnet for global capital. International investors commit billions across diverse sectors. A prominent US-led consortium, featuring David Blitzer and Blackstone, acquires the Indian Premier League's Royal ... |
| 31.03.2026 | Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2 | BEIJING and BRIDGEWATER, N.J., March 31, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (SSE: 603087) today announced that two pivotal phase 3 clinical trials, SUPER-1 and SUPER-2, evaluating investigative once-weekly insulin GZR4 Injec... |
| 31.03.2026 | 5 Things to Know
Wall Street’s rough month, Powell’s inflation outlook, GLP-1 subscription and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Tuesday. In a partnership you might not have seen coming, Warren Buffett is teaming up with the NBA’s Stephen Curry to revive his iconi... |
| 31.03.2026 | Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly | Novo Nordisk launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients pay lower, “predictable” monthly prices.
Eligible patients can choose between three-, six- or 12-month su... |
| 31.03.2026 | European stocks post worst month since 2022 as Iran war drags on | LONDON — European stocks rose on Tuesday but rounded-off their worst monthly performance in six years, as uncertainty over the trajectory of the Iran war lingers.
The pan-European Stoxx 600 climbed 0.43%, after briefly dipping into negative... |
| 30.03.2026 | As demand for GLP-1 pills and shots surges, healthy habits are still key | Getting your Trinity Audio player ready...
By JONEL ALECCIA, AP Health Writer
Whether they’re using weekly shots or daily pills, more Americans than ever are turning to anti-obesity drugs to lose weight and boost health.
About 1 in 8 U.S. a... |
| 27.03.2026 | Cellbricks Accelerates Organ Printing Vision with €10M Funding | Cellbricks Therapeutics secured €10M. This capital propels their biofabricated human tissue implants. The Berlin-Boston biotech firm revolutionizes regenerative medicine. Their proprietary light-based bioprinting platform creates vasculariz... |
| 26.03.2026 | Inside India newsletter: Ikea has high hopes for the country as it stares at a global slowdown | Monday - Friday, 11:00 - 12:00 SIN/HK | 0500 - 06:00 CET
The Swedish giant Ikea views India not only as a potential major retail market but also as a possible export hub, supported by the India‑EU free trade agreement finalized in January.
... |
| 25.03.2026 | Building the path to 3D-printed organs, Cellbricks raises €10M for biofabricated tissue implants | Berlin-founded biotech startup Cellbricks Therapeutics has raised €10 million to advance its goal of 3D-printed organs, beginning with biofabricated human tissue implants.
If successful, Cellbricks is not just building better implants — it ... |
| 23.03.2026 | ‘Well-positioned to navigate evolving landscape’: Novo Nordisk India-chief | - |
| 21.03.2026 | GLP-1 drugs are changing how Americans eat. Food companies are racing to catch up | For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses.
About one in every eight U.S. adults is currently taking a GLP-1 drug, like Ozempic or Zepbound, accord... |
| 21.03.2026 | Generic semaglutide versions roll out at prices pegged 80% less that Novo Nordisk’s Ozempic | - |
| 20.03.2026 | US FDA approves higher dose of Novo Nordisk's hit weight-loss drug Wegovy | - |
| 20.03.2026 | 5 Things to Know
The Dow’s losing streak, fertilizer prices, Novo Nordisk’s new Wegovy shot and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Friday. In a tale of two viral hotspots, Polymarket is planning a pop-up bar in Washington, D.C., while a New York City pharmacy is see... |
| 19.03.2026 | Nvidia Accelerates Open AI Frontier with Broad Model Expansion | Nvidia pushes open AI innovation. New models empower AI agents, physical systems, and healthcare. The company expands Nemotron for multimodal intelligence. It introduces Cosmos, GR00T, and Alpamayo for robotics and autonomous vehicles. BioN... |
| 19.03.2026 | Novo Nordisk’s semaglutide patent expiry on Friday — lower-cost generics poised for launch on Saturday | - |
| 19.03.2026 | FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share | The Food and Drug Administration approved a higher dose version of Novo Nordisk’s blockbuster weight loss injection Wegovy, as the company pushes to win back market share from Eli Lilly.
The high-dose Wegovy helped patients with obesity los... |
| 19.03.2026 | FDA approves new higher-dose version of Wegovy shots | Getting your Trinity Audio player ready...
By JONEL ALECCIA, AP Health Writer
Federal regulators on Thursday approved a new higher-dose version of the blockbuster obesity drug Wegovy that may help users lose more weight and keep it off. Rel... |
| 19.03.2026 | Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trial | Eli Lilly said its next-generation obesity drug retatutride cleared its first late-stage trial on Type 2 diabetes patients, helping them manage their blood sugar levels and lose weight.
The drug lowered hemoglobin A1C by an average of 1.7% ... |
| 17.03.2026 | NVIDIA Expands Open Model Families to Power the Next Wave of Agentic, Physical and Healthcare AI | announced it is expanding its open model families to power the next wave of agentic, physical and healthcare AI, introducing new models that enable developers and scientists to build intelligent systems that can reason and act across digita... |
| 14.03.2026 | Ohio State University Navigates Leadership Crisis Amid Scandal | Ohio State University confronts a leadership crisis. President Walter "Ted" Carter Jr. resigned suddenly. His departure followed revelations of an "inappropriate relationship" with a woman. She sought public resources fo... |
| 13.03.2026 | These stocks will benefit from AI and an aging population, Jefferies says. They also pay dividends | - |
| 12.03.2026 | NOTICE OF ANNUAL GENERAL MEETING IN GETINGE AB (PUBL) | NOTICE OF ANNUAL GENERAL MEETING IN GETINGE AB (PUBL)
Thu, Mar 12, 2026 08:00 CET Report this content
The shareholders of Getinge AB (publ), corporate ID No. 556408-5032, (“Getinge”) are hereby invited to attend the Annual General Meeting (... |
| 10.03.2026 | TD Cowen downgrades Novo Nordisk on concerns over semaglutide patent loss, pipeline outlook | - |
| 09.03.2026 | Ohio State University’s president resigns after reporting ‘inappropriate relationship’ | Getting your Trinity Audio player ready...
By JULIE CARR SMYTH
COLUMBUS, Ohio (AP) — Ohio State President Walter “Ted” Carter Jr. resigned on Monday after disclosing “an inappropriate relationship” with a woman seeking public resources for ... |
| 09.03.2026 | US stocks trim much of an early drop as market remains twitchy after oil spikes to nearly $120 | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — U.S. stocks trimmed much of an early loss amid growing concerns about whether the global economy can withstand spiking prices for oil, which briefly... |
| 09.03.2026 | Electrolyte supplements are everywhere. Who benefits from them and when? | Getting your Trinity Audio player ready...
By TRAVIS LOLLER
NASHVILLE, Tenn. (AP) — Social media is filled with influencers rating electrolyte supplements or even telling followers how to make their own. But experts say many of the claims a... |
| 09.03.2026 | Justice Department and Live Nation reach settlement over illegal monopoly case | Getting your Trinity Audio player ready...
By ALANNA DURKIN RICHER and LARRY NEUMEISTER
WASHINGTON (AP) — The Justice Department said Monday that it has tentatively settled its antitrust lawsuit against Ticketmaster and parent company Live ... |
| 09.03.2026 | Hims & Hers shares surge after Novo Nordisk drops patent infringement case over compounded weight loss drugs | “We have decided to drop the current court proceedings,” Novo CEO Mike Doustdar told CNBC on Monday, however, reserving the right to bring it back “if needed.”
It comes after an agreement between Novo and Hims where Hims will offer access t... |
| 09.03.2026 | Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration | Getting your Trinity Audio player ready...
By MICHELLE CHAPMAN, AP Business Writer
Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that wi... |
| 09.03.2026 | Crude oil prices spike as a broadening Iran war threatens both transport routes and production | Getting your Trinity Audio player ready...
By ALEX VEIGA, ELAINE KURTENBACH and WYATTE GRANTHAM-PHILIPS, AP Business Writers
Oil prices continued to soar on Monday as the Iran war intensified, threatening production and shipping in the Midd... |
| 09.03.2026 | Tax refunds are larger this year. Make yours a stepping stone for your future | Getting your Trinity Audio player ready...
By Ted Rossman, Bankrate.com
Tax refunds are the biggest windfall of the year for many American households. And ‘tis the season: Through the week ending Feb. 13, nearly 13 million people had receiv... |
| 09.03.2026 | Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyop... | Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company earned a $50 million milestone payment from Novo Nordisk related to the achievement of a prespecified enrollment target in the ongoing Phase 3 CLEOPATTRA clinical trial... |
| 09.03.2026 | Uber’s women-only option goes nationwide in the US | Getting your Trinity Audio player ready...
By ALEXANDRA OLSON, AP Business Writer
NEW YORK (AP) — Uber launched a feature Monday to allow both women riders and drivers across the U.S. to be matched with other women for trips, expanding a pi... |
| 07.03.2026 | Novo and Hims end feud, will sell obesity drugs together | - |
| 07.03.2026 | Should drug companies be advertising to consumers? | Getting your Trinity Audio player ready...
By Paula Span, KFF Health News
Tamar Abrams had a lousy couple of years in 2022 and ’23. Both her parents died; a relationship ended; she retired from communications consulting. She moved from Arli... |
| 06.03.2026 | Anti-obesity treatment could cost as little as US$3 per month: Study | PARIS: A blockbuster anti-obesity and diabetes drug could cost as little as US$3 per month to manufacture once it goes off patent later this month, researchers said on Friday (Mar 6), providing a major opportunity to boost health in low and... |
| 06.03.2026 | Zealand’s stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the ‘weight loss Olympics’ | Shares of Danish drugmaker Zealand Pharma fell more than 35% after trial patients lost less weight than expected with its experimental medicine.
CEO Adam Steensberg told CNBC that, in the real world, Zealand’s drug offers massive potential ... |
| 05.03.2026 | Novo Nordisk Fortifies Global Oral GLP-1 Supply with $506M Ireland Expansion | Novo Nordisk is investing €432 million ($506 million) to expand its oral GLP-1 manufacturing in Athlone, Ireland. This massive expansion boosts production capacity for international markets, excluding the U.S. It marks a critical strategic ... |
| 05.03.2026 | Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S. | Eli Lilly launched a new program designed to help more employers cover obesity drugs in the U.S., targeting a major barrier to access for patients.
The “Employer Connect” platform gives employers more flexibility in how they cover obesity t... |
| 03.03.2026 | Novo Nordisk: €432 Million Investment To Expand Irish Oral GLP-1 Manufacturing Capacity | Novo Nordisk A/S announced it will invest €432 million (approximately DKK 3.2 billion) to expand its manufacturing facility in Monksland, Athlone, Ireland, increasing production capacity for oral GLP-1 treatments serving markets outside the... |
| 02.03.2026 | Why Novo Nordisk’s Ireland expansion is key to fighting off Eli Lilly | Novo Nordisk is investing $506 million to expand manufacturing capabilities in Ireland.
The move will strengthen its ability to meet both current and future demand for its oral medicines, said Novo executive Kasper Bødker Mejlvang.
It comes... |
| 28.02.2026 | Anthropic vs. The Pentagon: what enterprises should do | The relationship between one of Silicon Valley's most lucrative and powerful AI model makers, Anthropic, and the U.S. government reached a breaking point on Friday, February 27, 2026.
President Donald J. Trump and the White House posted on ... |
| 28.02.2026 | Novo Nordisk Faces Setback as Key Weight Loss Drug Falls Short | Novo Nordisk experienced a significant blow. Its experimental weight-loss medication, CagriSema, failed to meet expectations in a crucial clinical trial. The drug did not demonstrate non-inferiority against Eli Lilly's rival product, tirzep... |
| 28.02.2026 | Novo Nordisk Slashes GLP-1 Drug Prices, Reshaping US Healthcare Access | Novo Nordisk announces significant price reductions for its flagship GLP-1 medications, Ozempic, Wegovy, and Rybelsus. List prices will drop by up to 50% starting January 2027. This strategic shift targets insured patients, particularly tho... |
| 27.02.2026 | Letter AI Secures $40 Million to Revolutionize Revenue Enablement with AI | Letter AI, a Chicago-based innovator, successfully raised $40 million in Series B funding. Battery Ventures championed the round. This significant capital influx will propel the company's AI-native revenue enablement platform. The platform ... |
| 27.02.2026 | Global Markets Reel: AI Shockwaves, Tariff Turmoil Drive Sell-Off | Global markets experienced a significant downturn. AI disruption rocked the cybersecurity sector. Anthropic's new tool triggered a sell-off in major security stocks, including IBM. Tariff uncertainty heightened economic fears. A Supreme Cou... |
| 27.02.2026 | Global Pharma Giants Bet Big on China's Weight-Loss Innovations | Pfizer significantly invests in China's surging weight-loss drug market. A landmark partnership with Sciwind Biosciences grants Pfizer exclusive commercialization rights for Ecnoglutide, a cutting-edge GLP-1 receptor agonist, in mainland Ch... |
| 27.02.2026 | Prothena Announces up to $100 Million Share Repurchase Plan | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of Directors has authorized ... |
| 27.02.2026 | Abbott to sell a second brand of Novo Nordisk’s diabetes drug Ozempic | - |
| 27.02.2026 | Clinical ink Appoints Dr. Christian Born Djurhuus, MD, PhD as Chief Science Officer | Expands leadership in cardiometabolic disease management and clinical trial technology
WINSTON-SALEM, N.C., Feb. 27, 2026 /PRNewswire-PRWeb/ -- Clinical ink, a global life science technology company, announced the appointment of Dr. Christi... |
| 26.02.2026 | Ozempic, Wegovy list prices to be slashed by up to 50% | Getting your Trinity Audio player ready...
Weight loss drugmaker Novo Nordisk will cut the list prices of Ozempic and Wegovy by up to 50% beginning in 2027, the company announced this week.
Wegovy currently carries a list price of $1,349 pe... |
| 25.02.2026 | Anthropic says Claude Code transformed programming. Now Claude Cowork is coming for the rest of the enterprise. | Anthropic opened its virtual "Briefing: Enterprise Agents" event on Tuesday with a provocation. Kate Jensen, the company's head of Americas, told viewers that the hype around enterprise AI agents in 2025 "turned out to be mos... |
| 25.02.2026 | These 4 charts show the scale of Novo Nordisk’s woes | Pricing pressure, fierce competition, and pipeline setbacks are all weighing on Novo Nordisk.
The Danish company is less diversified than current and future competitors, and increasingly exposed to the U.S. market, where drug prices are com... |
| 25.02.2026 | Direct-to-consumer sales for obesity drugs are about to boom. JPMorgan sees Eli Lilly as big winner | - |
| 25.02.2026 | Pfizer, Other Global Pharma Giants Are Pouring Big Bucks Into Licensing Chinese Weight-Loss Drugs | (Yicai) Feb. 25 -- Global pharmaceutical heavyweights, including the likes of Pfizer and AstraZeneca, are shelling out huge sums to secure the licensing rights to Chinese weight-loss drugs, as a fierce scramble for next-generation obesity t... |
| 25.02.2026 | Zydus to launch Semaglutide Injection in India on patent expiry | - |
| 24.02.2026 | Novo Nordisk trial ‘own goal’ sparks flurry of analyst downgrades | At least seven analysts cut their price targets on Novo Nordisk after disappointing results for its next-generation weight loss drug, CagriSema.
Confidence in the stock is now severely dented, and investors are doubting the medicine’s comme... |
| 24.02.2026 | Letter AI Raises $40M in Series B Funding | Letter AI, a Chicago, IL -based AI-native revenue enablement platform for go-to-market teams, raised $40m in Series B funding.
The round was led by Battery Ventures, with participation from Y Combinator, Lightbank, Northwestern Mutual Futur... |
| 24.02.2026 | Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients | Novo Nordisk on Tuesday said it plans to slash the monthly list prices of its popular obesity and diabetes drugs in the U.S. by up to 50% starting in 2027.
The move aims to make the treatments more accessible to patients with insurance cove... |
| 24.02.2026 | 5 Things to Know
Meta-AMD chip deal, Wall Street’s AI angst, Trump’s State of the Union and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Happy Tuesday. I found yesterday’s snowfall to be quite idyllic, granted I didn’t actually step foot outside until it had stopped (don’t repe... |
| 24.02.2026 | CNBC Daily Open: Unstable tariff situation and new AI disruption spark market sell-off | FedEx sued the U.S. government on Monday.
Panama annulled port contracts held by a subsidiary of Hong Kong-based CK Hutchison.
Canva acquired startups Cavalry and MangoAI.
U.S. stocks fell Monday on AI fears and tariff confusion.
Buy the di... |
| 24.02.2026 | Stocks making the biggest moves midday: IBM, AMD, Dillard’s, Novo Nordisk, Keysight Technologies & more | - |
| 24.02.2026 | Letter AI: $40 Million Series B Raised For AI-Native Revenue Enablement Platform | Letter AI, an AI-native revenue enablement platform for enterprise go-to-market teams, has raised $40 million in a Series B funding round led by Battery Ventures, with participation from Y Combinator, Lightbank, Northwestern Mutual Future V... |
| 24.02.2026 | Fat or Skinny Fat: Both Can Harm Your Health | Join the Anti-Obesity Health Base: Outsmart the Obesity Threat Together | HONG KONG, Feb. 24, 2026 /PRNewswire/ -- Hong Kong is a world-renowned food paradise, offering everything from local snacks like fish balls and egg waffles to Michelin-starred culinary experiences. However, maintaining a healthy weight amid... |
| 23.02.2026 | Eli Lilly’s lead in the obesity race gets wider after another win against rival Novo Nordisk | - |
| 23.02.2026 | Stocks making the biggest moves premarket: Arcellx, Novo Nordisk, Domino’s Pizza and more | - |
| 23.02.2026 | Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights | Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the fourth quarter and... |
| 23.02.2026 | Novo Nordisk sinks 15% after weight loss drug fails to match Eli Lilly’s in trial | Novo’s drug, CagriSema, didn’t achieve its key goal of demonstrating non-inferiority on weight loss when compared to Eli Lilly’s rival drug tirzepatide.
The stock plummeted on Monday, hitting its lowest level since June 2021.
The Danish dru... |
| 23.02.2026 | Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen | Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month’s worth of doses in a single pen.
The pen could serve as a more convenient option for some patients, as it reduces the number of devices ... |
| 23.02.2026 | US stocks drop after Trump ramps up his tariffs and worries flare about potential AI losers | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — U.S. stocks are falling Monday after President Donald Trump took little time to ramp up his newest tariffs, and as investors continue to punish comp... |
| 23.02.2026 | Novo Nordisk shares tumble after drug trial falls short | Shares in Danish drug giant Novo Nordisk have shed more than a sixth of their value after poor drug trial results sparked an investor selloff.
The firm behind weight-loss drugs Ozempic and Wegovy saw its shares tumble by 16.7 per cent to 25... |
| 21.02.2026 | Quantonation Secures €220M Quantum Fund, Fuels Deep Physics Revolution | Quantonation Ventures closed its second flagship fund at €220 million. This makes it the world's largest dedicated quantum investment firm. The move signals a critical shift in quantum technology. Investment now targets an interlocking ecos... |
| 20.02.2026 | Buy this best-in-class GLP-1 leader as competition heats up, says Barclays | - |
| 18.02.2026 | Quantonation Ventures closes €220M quantum fund backed by Toshiba | A Paris and New York-headquartered quantum technology VC firm has closed what it says is the “largest-ever” dedicated quantum fund.
Quantonation Ventures, an early-stage fund focusing on quantum tech, has closed a €220m fund, with investmen... |
| 18.02.2026 | Exclusive: NHS must keep medicine clawback down or lose investment, says weight-jab boss | The NHS must keep its medicines clawback tax low and predictable or else risk disrupting the rollout of weight-loss drugs in the UK, Novo Nordisk’s UK chief has said.
Sebnem Avsar Tuna, general manager of UK operations for the Ozempic and W... |
| 17.02.2026 | Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer | Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer
Tue, Feb 17, 2026 08:00 CET Report this content
Lund, Sweden — 17 February 2026 — Camurus (NASDAQ STO: CAMX) today announced that Jane Buus Laursen has been appointed... |
| 17.02.2026 | ALP AI receives CHF 40,000 from Venture Kick to translate organoid-AI platform into pilots | What was the first real signal that your solution worked outside the lab or pitch deck, and what did that moment change for you?
Our first signal wasn’t a graph, it was a room. We pitched ALP AI to experienced pharma and healthcare experts ... |
| 13.02.2026 | Prices, pipelines and patent cliffs: Inside pharma’s big reset | Pharma earnings weren’t the main focus for drugmakers this quarter.
“2025 was about understanding kind of the rules of the future of the game,” McKinsey Senior Partner Greg Graves told CNBC.
In addition to political dealings, companies are ... |
| 11.02.2026 | Novo Nordisk CEO sees 15 million patient opportunity in Medicare coverage for obesity drugs | Novo Nordisk CEO Mike Doustdar says the company is aiming to capture around 15 million new patients when Medicare starts covering obesity treatments.
Doustdar said he doesn’t expect Medicare access to obesity treatments, expected later this... |
| 10.02.2026 | 5 Things to Know
Coca-Cola earnings, Google’s AI risks, Target layoffs and more in Morning Squawk | This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox.
Good morning. Fresh off his feature in Salesforce’s Super Bowl ad, MrBeast is getting into banking. The YouTuber, whose real name is Jimmy Do... |
| 10.02.2026 | CNBC Daily Open: Takaichi and the AI trade in focus this week | S&P Global Ratings has lowered its forecast for China property sales in 2026.
Cuba says international airlines can no longer refuel on the island nation.
Novo Nordisk sues Hims & Hers.
The S&P 500 rose Monday, notching back-to-b... |
| 09.02.2026 | Stocks making the biggest moves premarket: Oracle, Novo Nordisk, Hims & Hers Health, Kroger and more | - |
| 09.02.2026 | US stocks drift higher as gold, silver and bitcoin stabilize | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — U.S. stocks drifted higher on Monday following big rallies for markets in Asia earlier in the day. Related Articles
Colorado looks to end top 25 roa... |
| 09.02.2026 | Novo Nordisk Foundation: BioInnovation Institute Launches Upscalator With Up To €25 Million | The Novo Nordisk Foundation has allocated up to €25 million to launch a new initiative called Upscalator, designed to help early-stage Danish and European biosolutions startups scale their technologies toward market readiness and support th... |
